Loading stock data…
$22.73-0.36 (-1.58%)
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Zai Lab Limited in the Healthcare sector is trading at $22.73 with a market capitalization of $2.9B. Wall Street consensus targets $33.14 (12 analysts), implying a +45.8% move over the next 12 months. The stock is currently 25% below its 52-week high of $30.18, remaining 10.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $106.31M↑ | $99.61M↓ | $127.60M↑ | $116.09M↑ | $109.98M |
| Gross Profit | $58.15M↓ | $61.28M↓ | $65.27M↓ | $69.21M↑ | $66.76M |
| Operating Income | -$76.49M↓ | -$69.28M↓ | -$68.26M↓ | -$47.97M↑ | -$54.90M |
| Net Income | -$50.83M↑ | -$51.02M↓ | -$50.41M↓ | -$35.96M↑ | -$40.73M |
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products includ...